RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy (NK) Clinical Trial with RGN-259 (PR Newswire)

Data Expected in Early 2016 ROCKVILLE, Md., Sept. 21, 2015 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that the first patient has been enrolled in a Phase 3 clinical trial with RGN-259 (designated GBT-201 in Korea), its sterile,…

You may also like...